Literature DB >> 19570496

Understanding needs, interactions, treatment, and expectations among individuals affected by bipolar disorder or schizophrenia: the UNITE global survey.

Roger S McIntyre1.   

Abstract

OBJECTIVE: The overarching aim of the Understanding Patients' Needs, Interactions, Treatment, and Expectations (UNITE) Global Survey was to empirically evaluate the attitudes and general fund of knowledge that individuals with bipolar disorder or schizophrenia possess regarding somatic health issues.
METHOD: The UNITE survey was an Internet-based initiative that recruited patients and caregivers from 11 countries (Australia, Brazil, France, Greece, Germany, Italy, Spain, South Korea, Sweden, the United States, and the United Kingdom). Opinion Research Corporation, Princeton, NJ, conducted the UNITE survey between June 10, 2006, and September 11, 2006, and analyzed the results.
RESULTS: A total of 5,074 respondents participated in the survey. From this total sample, 1,155 individuals with schizophrenia and 1,300 with bipolar disorder were self-identified. Psychiatrists were identified as the individuals primarily responsible for patients' medication prescription and surveillance of both psychological and physical health. The majority of respondents in both groups had been receiving medication for more than 5 years. Weight gain was the most commonly cited adverse event associated with medication use. Moreover, weight gain was identified as a contributing factor to general medical comorbidity (eg, diabetes mellitus) and as a detractor to quality of life. Most respondents identified weight gain and general physical health as areas of deficiency in their perceived knowledge and interactions with health care providers. Notwithstanding the ubiquity and implications of comorbid medical disorders and medication-related adverse events, most respondents did not receive opportunistic screening or surveillance for medical risk factors and disorders. Overall, respondents expressed general dissatisfaction when interacting with mental health care providers.
CONCLUSION: Metabolic consequences of psychotropic medication are the most concerning aspect of medication treatment for patients, contributing to perceived morbidity, quality-of-life reduction, and reduced satisfaction with care. Despite the compelling database that underscores the hazards attributable to comorbid general medical conditions, most individuals with schizophrenia and bipolar disorder receive guideline-discordant care for somatic health conditions as well as for the principal psychiatric disorder. Barriers to somatic health care access for those with schizophrenia and bipolar disorder, as well as the impact of targeted interventions, warrant future research. © Copyright 2009 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19570496     DOI: 10.4088/JCP.7075su1c.02

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  19 in total

1.  Identifying clinical net benefit of psychotropic medication use with latent variable techniques: Evidence from Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).

Authors:  Natalie Bareis; Juan Lu; Cynthia K Kirkwood; Susan G Kornstein; Elwin Wu; Briana Mezuk
Journal:  J Affect Disord       Date:  2018-05-29       Impact factor: 4.839

2.  An epidemiologic and clinical overview of medical and psychopathological comorbidities in major psychoses.

Authors:  A Carlo Altamura; Marta Serati; Alessandra Albano; Riccardo A Paoli; Ira D Glick; Bernardo Dell'Osso
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-02-18       Impact factor: 5.270

Review 3.  Atypical antipsychotics: recent research findings and applications to clinical practice: Proceedings of a symposium presented at the 29th Annual European College of Neuropsychopharmacology Congress, 19 September 2016, Vienna, Austria.

Authors:  Robin Murray; Christoph U Correll; Gavin P Reynolds; David Taylor
Journal:  Ther Adv Psychopharmacol       Date:  2017-03-01

4.  The 'new normal': relativity of quality of life judgments in individuals with bipolar disorder-a qualitative study.

Authors:  Emma Morton; Erin Michalak; Rachelle Hole; Simone Buzwell; Greg Murray
Journal:  Qual Life Res       Date:  2018-02-12       Impact factor: 4.147

Review 5.  Which rating scales are regarded as 'the standard' in clinical trials for schizophrenia? A critical review.

Authors:  Takefumi Suzuki
Journal:  Psychopharmacol Bull       Date:  2011

6.  The effect of bariatric surgery on psychiatric course among patients with bipolar disorder.

Authors:  Ameena T Ahmed; E Margaret Warton; Catherine A Schaefer; Ling Shen; Roger S McIntyre
Journal:  Bipolar Disord       Date:  2013-08-05       Impact factor: 6.744

7.  Review of the safety, efficacy, and side effect profile of asenapine in the treatment of bipolar 1 disorder.

Authors:  Jodi M Gonzalez; Peter M Thompson; Troy A Moore
Journal:  Patient Prefer Adherence       Date:  2011-07-01       Impact factor: 2.711

8.  Attitudes toward metabolic adverse events among patients with schizophrenia in Japan.

Authors:  Norio Sugawara; Norio Yasui-Furukori; Manabu Yamazaki; Kazutaka Shimoda; Takao Mori; Takuro Sugai; Hiroshi Matsuda; Yutaro Suzuki; Yoshitake Minami; Yuji Ozeki; Kurefu Okamoto; Toyoaki Sagae; Toshiyuki Someya
Journal:  Neuropsychiatr Dis Treat       Date:  2016-02-24       Impact factor: 2.570

Review 9.  Unmet needs of bipolar disorder patients.

Authors:  Miroslav Hajda; Jan Prasko; Klara Latalova; Radovan Hruby; Marie Ociskova; Michaela Holubova; Dana Kamaradova; Barbora Mainerova
Journal:  Neuropsychiatr Dis Treat       Date:  2016-06-24       Impact factor: 2.570

10.  THE MANAGEMENT OF CARDIOVASCULAR DISEASE RISK FACTORS IN BIPOLAR DISORDER PATIENTS IN PRIMARY HEALTHCARE SETTINGS.

Authors:  Sandra I Ralat; Rossana I Barrios
Journal:  Rev Puertorriquena Psicol       Date:  2020 Jan-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.